Utrecht

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Colorectal cancer3 trials
• Multiple myeloma3 trials
• HIV2 trials
• Endometrial cancer1 trial
• Pancreatic cancer1 trial

Phase

• Phase 1/25 trials
• Phase 32 trials
• Phase 21 trial

Status

• Active, not recruiting6 trials
• Recruiting2 trials

Lead sponsor

• GlaxoSmithKline6 trials
• ViiV Healthcare2 trials

Running trials

• Recruiting

  A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

  NCT07213609· Phase 1/2· GlaxoSmithKline· Source

  Contact: Eelke Gort (principal investigator)

• Recruiting

  A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)

  NCT06885034· Phase 1/2· GlaxoSmithKline· Source

  Contact: Robert Jan Kwakman (principal investigator)

• Active, not recruiting

  A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

  NCT05723562· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM

  NCT07084896· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

  NCT07217119· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

  NCT04126200· Phase 1/2· GlaxoSmithKline· Source

• Active, not recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants

  NCT02938520· Phase 3· ViiV Healthcare· Source

• Active, not recruiting

  Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients

  NCT02362503· Phase 3· ViiV Healthcare· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer2 recruiting
• Endometrial cancer1 recruiting
• Pancreatic cancer1 recruiting